Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | MT-CO2 | P00403 | 3/20 | 1.00 |
| ▸ | CA12 | O43570 | 2/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 1.00 |
| ▸ | CA2 | P00918 | 2/20 | 1.00 |
| ▸ | CA9 | Q16790 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CA3 | P07451 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | CA4 | P22748 | 1/20 | 1.00 |
| ▸ | CA6 | P23280 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valdecoxib SCHEMBL3853130 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1MT-CO2CA12CA1 | |
| Valdecoxib SCHEMBL3356 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1MT-CO2CA12CA1 | |
| Valdecoxib SCHEMBL6601157 | 0.99 | PTGS2 (0.97) | PTGS2PTGS1MT-CO2CA12CA1 | |
| Valdecoxib SCHEMBL5999213 | 0.99 | PTGS2 (0.97) | PTGS2PTGS1MT-CO2CA12CA1 | |
| Valdecoxib SCHEMBL5998054 | 0.94 | PTGS2 (0.88) | PTGS2PTGS1MT-CO2CA12CA1 | |
| Valdecoxib SCHEMBL6598685 | 0.94 | PTGS2 (0.88) | PTGS2PTGS1MT-CO2CA12CA1 | |
| SCHEMBL6170420 | 0.90 | PTGS2 (0.82) | PTGS2PTGS1MT-CO2CA12CA1 | |
| Sulfamide SCHEMBL4638912 | 0.90 | PTGS2 (0.81) | PTGS2PTGS1MT-CO2CA12CA1 | |
| SCHEMBL28961699 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1MT-CO2CA12CA1 | |
| SCHEMBL31213504 | 0.88 | PTGS2 (0.78) | PTGS2PTGS1MT-CO2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0809636-B1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-04 | — | — | EP | claimed |
| CN-109970673-B | Preparation method of parecoxib sodium impurity | 北京康派森医药科技有限公司 | 2021-02-19 | — | — | CN | disclosed |
| EP-2075011-A2 | Prodrugs Containing Bio-Cleavable Linkers | Piramal Life Sciences Limited (IN) | 2009-07-01 | — | — | EP | disclosed |
| US-20070060629-A1 | Large conductance calcium-activated k channel opener | TANABE SEIYAKU CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| US-20070060629-A1 | Large conductance calcium-activated k channel opener | TANABE SEIYAKU CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1528059-A2 | Substituted isoxazoles for the treatment of inflammation | G.D. Searle LLC (US) | 2005-05-04 | — | — | EP | disclosed |
| CN-1442139-A | Medicinal composition for treating inflammation | SEARLE & CO (US) | 2003-09-17 | — | — | CN | disclosed |
| CN-1107058-C | Substituted isoxazoles for the treatment of disorders | SEARLE & CO (US) | 2003-04-30 | — | — | CN | disclosed |
| EP-0809636-B1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1223167-A2 | Substituted isoxazoles for the treatment of inflammation | G.D. Searle & Co. (US) | 2002-07-17 | — | — | EP | disclosed |
| CN-1181075-A | Substituted isoxazoles for the treatment of disorders | SEARLE & CO (US) | 1998-05-06 | — | — | CN | disclosed |
| EP-0809636-A1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996025405-A1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060629-A1 | Large conductance calcium-activated k channel opener | KCNN3, KCNN1, KCNN2 | PTGS2 594/4885PTGS1 558/4885MT-CO2 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.